(1)
Lyon, 9 March 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announced that it has extended the capabilities of Neurolead, its drug candidate discovery platform, to include autophagy and neurological manifestations of lysosomal storage disorders.
Neurolead, which combines the latest innovations in neuroscience and artificial intelligence, is a platform for the generation of new drug candidates based on a unique concept, the therapeutic targeting of interactions between glial and neuronal cells. By applying Neurolead to autophagy and neurological forms of lysosomal storage disorders, Theranexus is taking its research in the direction of exploring a therapeutic avenue of major interest with clear medical and economic potential.